美股市场个股详情
NUVL Nuvalent
- 77.870
- -2.430-3.03%
收盘价 12/30 16:00 (美东)
- 77.510
- -0.360-0.46%
盘前 05:30 (美东)
55.33亿总市值-22.31市盈率TTM
80.720最高价76.860最低价60.78万股成交量80.720今开80.300昨收4741.79万成交额1.49%换手率亏损市盈率(静)7105.26万总股本113.51052周最高4.94市净率31.70亿流通值61.79552周最低--股息TTM4071.19万流通股113.510历史最高--股息率TTM4.81%振幅7.090历史最低78.016平均价1股每手
关于Nuvalent公司
Nuvalent, Inc.是一家临床阶段的生物制药公司，专注于为癌症患者创造精确靶向治疗。其产品线包括ROS1 NSCLC、ALK NSCLC和HER2 NSCLC。
公司介绍
公司代码NUVL
公司名称Nuvalent
上市日期2021/07/29
发行价格17.00
成立日期2017
CEODr. James R. Porter, PhD
所属市场纳斯达克
员工数量92
年结日12-31
公司地址One Broadway,14th floor
城市Cambridge
省份马萨诸塞州
国家美国
邮编02142
电话1-857-357-7000
董事高管
- 姓名
- 职务
- 年薪
- Dr. Matthew Shair, PhD
- Director, Scientific Founder and Head Scientific Advisor
- 68.82万
- Dr. James R. Porter, PhD
- Director, Chief Executive Officer and President
- 937.69万
- Dr. Deborah Miller, J.D.,PhD
- Chief Legal Officer and Secretary
- --
- Darlene Noci, A.C.I.S.
- Chief Development Officer
- --
- Dr. Christopher D. Turner, M.D.
- Chief Medical Officer
- 360.32万
- Alexandra Balcom, M.B.A.
- Chief Financial Officer, Principal Accounting Officer and Treasurer
- 354.16万
- Grant Bogle
- Independent Director
- --
- Dr. Sapna Srivastava, PhD
- Independent Director
- 50.32万
- Dr. Michael L. Meyers, M.D.,PhD
- Independent Director
- 49.44万
- Anna Protopapas
- Independent Director
- 52.32万
- Dr. Joseph Pearlberg, M.D.,PhD
- Independent Director
- 49.40万
- Dr. Emily Drabant Conley, PhD
- Independent Director
- 49.59万
- Dr. Andrew A. F. Hack, M.D.,PhD
- Independent Director
- 49.57万
- Dr. D. Gary Gilliland, M.D.,PhD
- Independent Director
- 49.57万
- Dr. Cameron A. Wheeler, PhD
- Independent Director
- 49.95万
热议
美股
综合热度
股票代码
最新价
涨跌幅
暂无数据